Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Treatment for acute severe ulcerative colitis

A comparative evaluation of the clinical effectiveness of ciclosporin versus infliximab for acute severe ulcerative colitis was reported recently. 270 patients with acute severe ulcerative colitis that failed to respond to intravenous hydrocortisone within 5 days were randomly allocated to receive infliximab or ciclosporin. No statistically significant differences between groups were noted for quality-adjusted survival, frequency of colectomy, mean time to colectomy, or number of serious adverse events.


  1. 1

    Williams, J. G. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol. Hepatol.

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Leake, I. Treatment for acute severe ulcerative colitis. Nat Rev Gastroenterol Hepatol 13, 436 (2016).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing